Drugs / LNA043
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT04564053 | Sep → Dec 2020 | osteoarthritis, knee | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02491281 | Nov 2015 → Feb 2018 | osteoarthritis, knee | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT04814368 | Aug 2021 → Jun 2024 | osteoarthritis, knee | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04864392 | May 2021 → Sep 2024 | osteoarthritis | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 2 | NCT03334812 | Oct 2017 → Apr 2019 | osteoarthritis, knee | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 2 | NCT03275064 | Sep 2017 → Sep 2022 | osteoarthritis | Novartis Pharmaceuticals | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNA043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03275064 ↗ |
| Route | Other | “LNA043 given intra-articularly into the human knee joint” NCT02491281 ↗ |